Personalis (NASDAQ:PSNL) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Personalis (NASDAQ:PSNL) in a research report sent to investors on Friday,Benzinga reports. The firm currently has a $7.25 target price on the stock.

Personalis Stock Performance

Shares of PSNL stock opened at $5.75 on Friday. Personalis has a 1 year low of $1.12 and a 1 year high of $7.20. The business’s fifty day moving average is $4.37 and its 200-day moving average is $3.89. The stock has a market cap of $406.23 million, a PE ratio of -3.42 and a beta of 1.88.

Personalis (NASDAQ:PSNL) last released its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The firm had revenue of $25.71 million for the quarter, compared to analyst estimates of $20.67 million. During the same period in the previous year, the firm earned ($0.51) earnings per share. Equities research analysts predict that Personalis will post -1.41 earnings per share for the current year.

Institutional Trading of Personalis

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC grew its position in Personalis by 11.4% in the third quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after buying an additional 723,637 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Personalis by 6.7% during the 2nd quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock worth $1,237,000 after acquiring an additional 66,128 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Personalis by 20.0% in the 3rd quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock worth $2,683,000 after acquiring an additional 83,068 shares during the last quarter. State Street Corp raised its position in shares of Personalis by 34.5% during the third quarter. State Street Corp now owns 175,142 shares of the company’s stock worth $942,000 after purchasing an additional 44,900 shares during the period. Finally, Walleye Capital LLC purchased a new stake in shares of Personalis during the third quarter valued at $897,000. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.